AssayIndex
Growth-hormone axis peptides

Follistatin-344

FS-344 · recombinant follistatin · recombinant protein (344 aa). The index holds 5 assay reports on this compound across 1 batches from 1 suppliers.

5 reports1 batchesmedian index spec 98.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Follistatin-344 is a 38 kDa glycoprotein and RP-HPLC purity is not a defined quantity for it. The index records follistatin submissions with purity marked NOT APPLICABLE and reports only what can honestly be measured: SDS-PAGE band pattern, SEC monomer fraction, total protein by BCA, endotoxin, and host-cell-protein and residual-DNA figures where a supplier provides them. None do. Every follistatin record here therefore reads as a documentation gap rather than a quality assessment, and that is the finding.

Molecular formula
recombinant protein (344 aa)
Monoisotopic mass
not defined
Average mass
38000.00Da
Residues
344
Nominal retention (RG-2, 30 min)
not defined
Retention window
Counter-ion as usually shipped
none expected
Typical label claims
0.1 mg · 1 mg
Analytical difficulty (index scale)
1.90 — hard
Purity is a defined quantity
NO
Section 3

What the index has observed

Arithmetic over the 5 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

The index holds 5 records for Follistatin-344, and purity is not a defined quantity for it. That is a gap in the index, not a finding about the compound.

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area

Degradation pathways

  • aggregation
  • proteolytic clipping during expression and purification
  • glycosylation heterogeneity where expressed in a eukaryotic system

Full impurity profile, with what each named species implies about the synthesis →

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3
2024-Q20n<3
2024-Q30n<3
2024-Q40n<3
2025-Q15n<3
2025-Q20n<3
2025-Q30n<3
2025-Q40n<3
2026-Q10n<3
2026-Q20n<3
2026-Q30n<3

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Follistatin-344 records of 5.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-019993ERPERP-2411-Y6431Nordanalyt2025-Q1N/A3.72Supplier-supplied1N/A
AX-2025-019995ERPERP-2411-Y6431Medutest2025-Q1N/A2.81Supplier-supplied1N/A
AX-2025-019997ERPERP-2411-Y6431VendorInvestigate2025-Q1N/A2.68Buyer-sourced1N/A
AX-2025-019996ERPERP-2411-Y6431Medutest2025-Q1N/A2.97Supplier-supplied1N/A
AX-2025-019994ERPERP-2411-Y6431Medutest2025-Q1N/A2.74Buyer-sourced1N/A